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Background: The purpose of this prospective study was to investigate the intraocular pressure 
(IOP)-lowering effect and safety of latanoprost 0.005% + timolol maleate 0.5% fixed combina-
tion eyedrops, now available in Japan.
Materials and methods: Thirty-one patients diagnosed with primary open-angle glaucoma 
who had an insufficient intraocular pressure (IOP) decrease with latanoprost 0.005% eyedrop 
monotherapy were enrolled. The latanoprost 0.005% eyedrops were discontinued, and admin-
istration of latanoprost 0.005%/timolol maleate 0.5% fixed combination eyedrops was initiated 
without any washout period. IOP was compared before and at months 1, 3, and 6 after the switch. 
The incidence of adverse reactions was investigated at every follow-up visit.
Results: Mean IOP was 17.3 ± 2.7 mmHg before the switch, 15.5 ± 2.6 mmHg one month after 
the switch, 14.9 ± 2.4 mmHg 3 months after the switch, and 15.1 ± 2.2 mmHg 6 months after 
the switch, indicating that IOP decreased significantly after the change. The IOP reduction rate 
was 9.9% ± 11.5% after one month, 13.1% ± 10.9% after 3 months, and 11.2% ± 11.8% after 
6 months. Two patients (6.5%) discontinued therapy due to adverse reactions (one case each 
of itchiness and bradycardia).
Conclusion: When latanoprost 0.005% eyedrop monotherapy was replaced by latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrops, IOP decreased significantly without 
increasing the frequency of administration, and safety was satisfactory.
Keywords: latanoprost 0.005%, timolol maleate 0.5%, fixed combination, eyedrops, intraocular 
pressure, switch
Introduction
The goal of treatment of patients diagnosed with glaucoma is preservation of visual 
function. Intraocular pressure (IOP)-lowering therapy is the only alternative that 
shows evidence of adequate preservation of the visual field.1,2 Generally, medical 
treatment is the first approach to decreasing IOP. Prostaglandin-related eyedrops 
are the primary therapy due to their powerful IOP-decreasing effects, their low 
incidence of systemic side effects, and their convenient once-daily   administration. 
However, in cases where the IOP decrease is insufficient with monotherapy, a switch 
to another medication or initiation of adjunctive therapy is necessary. In multidrug 
cases where the frequency of administration increases, decreased adherence is a 
problem,3 so the most suitable option is once-daily administration of fixed com-
bination eyedrops. In Japan, the latanoprost 0.005% + timolol maleate 0.5% fixed 
combination eyedrop (Xalacom®; Pfizer Japan Inc, Japan, Tokyo) formulation was 
released in April 2010.
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The present study involved patients with primary   open-angle 
glaucoma who were initially treated with latanoprost 
0.005% eyedrop monotherapy. We investigated the IOP-
decreasing effect and safety of a switch to latanoprost 
0.005% + timolol maleate 0.5% fixed combination 
eyedrops.
Materials and methods
This study included 31 eyes from 31 patients (12 men, 
19 women) diagnosed with primary open-angle glaucoma 
(including normal tension glaucoma) and treated at Inouye 
Eye Hospital between May 2010 and June 2011. The patients 
were using latanoprost monotherapy and had inadequate IOP 
control. Their mean age was 63.0 ± 12.4 (range 31–79) years. 
  Twenty-one patients had primary open-angle glaucoma and 
10 had normal tension glaucoma. The mean deviation in 
Humphrey visual field was −7.2 ± 5.9 (range −27.46–1.45) dB. 
The mean IOP before switching to latanoprost 0.005% + timolol 
maleate 0.5% fixed combination eyedrops was 17.3 ± 2.7 
(range 12–23) mmHg. If both eyes met the eligibility criteria, 
the eye with the higher IOP was selected; if the IOP was equiva-
lent in both eyes, the right eye was selected for treatment. In a 
monocular case, the affected eye was used for analysis.
The patients discontinued latanoprost 0.005% eyedrops 
and switched to latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrops (once daily at night) without any 
washout period. Eyedrops were administered at the same 
time of the day, and IOP was measured before and at 1, 3, 
and 6 months after the switch by the same examiner using 
a Goldmann applanation tonometer at the same time of day. 
IOP before and at 1, 3, and 6 months after the switch was 
compared by analysis of variance and Bonferroni/Dunnett’s 
tests. IOP reduction at 1, 3 and 6 months after the switch was 
calculated and compared. After the switch, the incidence of 
adverse reactions was investigated at every follow-up visit. 
The statistical significance level in all cases was P , 0.05. 
The study was approved by the ethics committee of Inouye 
Eye Hospital, and conducted according to the Declaration of 
Helsinki after explaining the purpose and details of the study 
to the patients and obtaining informed consent in writing. 
Institutional review board approval was sought before any 
procedures were performed.
Results
The mean IOP was 15.5 ± 2.6 mmHg one month after the 
switch, 14.9 ± 2.4 mmHg 3 months after the switch, and 
15.1 ± 2.2 mmHg 6 months after the switch. There was 
a significant decrease in IOP compared with the mean 
baseline value of 17.3 ± 2.7 mmHg before the switch 
(P , 0.0001, Figure 1). At 6 months after the switch, IOP 
had decreased by more than 2 mmHg in 17 cases (60.7%) 
and was within 1 mmHg in 11 cases (39.3%, Figure 2). 
Mean IOP reduction was 1.8 ± 2.2 mmHg one month after 
the switch, 2.4 ± 2.2 mmHg 3 months after the switch, 
and 2.1 ± 2.3 mmHg 6 months after the switch, which 
was not significantly different (P = 0.6408). The mean 
IOP reduction rate was 9.9% ± 11.5% one month after 
the switch, 13.1% ± 10.9% 3 months after the switch, and 
11.2% ± 11.8% 6 months after the switch, which was not 
significantly different (P = 0.5682).
Adverse reactions appeared in two cases (6.5%), 
including one case each of itching and bradycardia. 
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Figure 1 Intraocular pressure before and after the switch to the fixed combination of latanoprost and timolol maleate. 
Notes: Analysis of variance, Bonferroni/Dunnett’s test, *P , 0.0001.
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After   discontinuation of the latanoprost 0.005% + timolol 
maleate 0.5% combination, the symptoms immediately 
disappeared. One patient discontinued as a result of stopping 
coming to the hospital after 5 months.
Discussion
If the decrease in IOP is insufficient with latanoprost 0.005% 
eyedrop monotherapy, β-blocker or carbonic anhydrase 
inhibitor eyedrops can be added to the regimen, or medication 
can be switched to fixed combination eyedrops. When fixed 
combination eyedrops are used instead of combined therapy, 
the administration frequency decreases, adherence improves, 
and IOP may decrease. The administration   frequency for 
latanoprost 0.005% + timolol maleate 0.5% fixed combi-
nation eyedrops is once daily, but the original administra-
tion frequency for timolol maleate 0.5% eyedrops is twice 
daily, so there is a concern that there could be a reduction 
in efficacy. Thus, it is of interest whether the IOP decrease 
associated with latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrop monotherapy is equal to that 
associated with concomitant use of latanoprost 0.005% and 
timolol maleate 0.5% eyedrops. We have previously reported 
on hypotensive efficacy in 162 patients diagnosed with 
primary open-angle glaucoma or ocular hypertension who 
were switched from concomitant use of latanoprost 0.005% 
eyedrops and timolol maleate 0.5% eyedrops to latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrops.4 
The mean IOP was 15.2 ± 3.3 mmHg before the switch and 
15.1 ± 3.2 mmHg 3 months after the switch, indicating that 
there was no significant difference in efficacy. Diestelhorst 
et al randomly assigned patients to latanoprost 0.005% + 
timolol maleate 0.5% fixed combination eyedrops (255 cases) 
or use of latanoprost 0.005% eyedrops and timolol maleate 
0.5% eyedrops concomitantly (247 cases) in a double-blind 
study among patients diagnosed with primary open-angle 
glaucoma, ocular hypertension, pigmentary glaucoma, or 
exfoliation glaucoma.5 After 12 weeks of administration, IOP 
reduction associated with the latanoprost 0.005% + timolol 
maleate 0.5% fixed combination eyedrop monotherapy 
group was 8.7 ± 0.2 mmHg, and that of the concomitant 
latanoprost 0.005% eyedrops and timolol maleate 0.5% 
eyedrops group was 9.0 ± 0.2 mmHg, indicating that there 
was no significant difference between the groups. However, 
adverse reactions appeared significantly less often among 
patients in the latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrop monotherapy group (P , 0.05). 
Findings from a switching study4 and a double-masked study5 
have indicated that the IOP decrease appears to be identical 
for patients who use latanoprost 0.005% and timolol maleate 
0.5% eyedrops concomitantly and those who use latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrop 
monotherapy.
There have been many reports of hypotensive effects 
following a switch from latanoprost 0.005% eyedrop 
monotherapy to latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrops.6–9 Kitazawa et al administered 
latanoprost 0.005% eyedrops for 4 weeks to 289 patients 
with primary open-angle glaucoma and ocular hypertension.6 
Afterwards, they divided the patients into latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrops 
and latanoprost 0.005% monotherapy groups, and continued 
treatment for a further 8 weeks. In the latanoprost 0.005% + 
timolol maleate 0.5% fixed combination eyedrops group, 
mean IOP was 19.62 ± 2.60 mmHg before the switch, but was 
decreased to 17.03 ± 2.67 mmHg 8 weeks after the switch. 
Mean IOP reduction was 2.59 ± 2.40 mmHg and the IOP 
reduction rate was 12.7% ± 12.1%. Dunker et al evaluated 
IOP among 51 patients with either exfoliation glaucoma, 
ocular hypertension, or pigmentary glaucoma for 6 months 
after an identical switch.7 There was a significant decrease 
in mean IOP 6 months after the switch (17.7 ± 3.6 mmHg) 
compared with beforehand (20.7 ± 3.6 mmHg). Mean IOP 
reduction was 2.9 ± 3.6 mmHg. Hamacher et al evaluated 
the IOP of 69 patients with exfoliation glaucoma, ocular 
hypertension, or pigmentary glaucoma for more than 
2 months after the same switch.8 The IOP after the switch 
(17.8 ± 2.9 mmHg) was significantly decreased compared 
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Figure 2 Reductions in intraocular pressure 6 months after the switch to the fixed 
combination of latanoprost and timolol maleate.
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with that beforehand (20.8 ± 3.4 mmHg). Mean IOP   reduction 
was 3.1 ± 3.6 mmHg. Polo et al evaluated IOP among 
33   primary open-angle glaucoma or exfoliative glaucoma 
patients for 3 months after an identical switch.9 Mean IOP one 
month after the switch (14.90 ± 1.86 mmHg) and 3 months 
after the switch (15.66 ± 1.91 mmHg) was significantly 
decreased compared with beforehand (20.38 ± 5.33 mmHg). 
Mean IOP reduction value and IOP reduction rate were 
5.48 mmHg and 23.5%, respectively, one month after the 
switch, and 4.71 mmHg and 19.5%, respectively, 3 months 
after the switch. The mean IOP reduction and IOP reduction 
rate was 1.8–2.3 mmHg and 10.3%–12.6%, respectively, 
in the present study, which is a little lower than the values 
reported previously.6–9 This is probably because the mean 
IOP before the switch was a little lower in the present 
study (17.3 ± 2.7 mmHg) compared with previous reports 
(19.6–20.8 mmHg).6–9
Hypotensive effects have previously been reported 
when a β-blocker is added to latanoprost therapy.10,11 
Miura et al administered timolol maleate 0.5% eyedrops 
as adjunctive therapy for 12 weeks to 15 primary open-
angle glaucoma or ocular hypotension patients already 
receiving latanoprost 0.005% eyedrop monotherapy.10 
IOP 12 weeks after initiation of the adjunctive therapy 
was significantly decreased (15.8 ± 3.2 mmHg) compared 
with baseline (18.5 ± 3.7 mmHg), and mean IOP reduction 
was 2.7 ± 2.3 mmHg. Liu et al administered 0.5% timolol 
gel-forming solution as an adjunctive therapy for 8 weeks 
to 26 patients who were diagnosed with either glaucoma 
or ocular hypertension.11 IOP after 8 weeks of adjunctive 
therapy (15.4 ± 2.3 mmHg) was also significantly decreased 
compared with baseline (23.0 ± 1.8 mmHg). Mean IOP 
reduction was 6.2 ± 2.8 mmHg, and the mean IOP reduction 
rate was 27.0%. When comparing the present study with pre-
vious studies10,11 of adjunctive therapy using timolol maleate 
0.5% eyedrops, mean IOP reduction was 1.8–2.3 mmHg in 
the present study and so a little lower than the 1.9–6.2 mmHg 
observed in the previous studies.10,11 IOP before the switch 
in the present study (17.3 ± 2.7 mmHg) was a little lower 
than IOP before initiation of adjunctive therapy reported 
previously (17.3–23.0 mmHg).10,11 It is thought that IOP 
reduction is almost identical when latanoprost 0.005% eye-
drops are switched to either latanoprost 0.005% + timolol 
maleate 0.5% fixed combination eyedrops or concomitant 
use of latanoprost 0.005% eyedrops and timolol maleate 
0.5% eyedrops.
Adverse reactions associated with latanoprost 0.005% + 
timolol maleate 0.5% fixed combination eyedrops include 
hyperemia, stimulation, foreign body sensation,   conjunctivitis, 
and keratitis.4–10 No serious adverse reactions have been 
reported previously,4–10 and none were observed in the pres-
ent study. The latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrops contains a β-blocker, but blood 
pressure and pulse rate were not evaluated in the present 
study. One case of unexpected bradycardia was identified 
because the patient’s blood pressure and pulse were regularly 
checked. Systemic adverse reactions, such as those affecting 
the cardiovascular and respiratory systems, can be induced 
by β-blockers, so careful patient monitoring is required.
The weaknesses of the present study are that the number 
of cases was small (n = 31), it was not blinded, and it did 
not include a control group. Moreover, when switching 
eyedrops, there is the possibility that adherence improves, 
resulting in a IOP decrease. Because there were only 
31 subjects, the spread of IOP and standard deviation became 
large. In conclusion, when latanoprost 0.005% eyedrop 
monotherapy was switched to latanoprost 0.005% + timolol 
maleate 0.5% fixed combination eyedrops in   Japanese 
patients with primary open-angle glaucoma, mean IOP 
decreased significantly without an increase in frequency of 
administration, and safety was satisfactory. Nevertheless, 
when β-blockers are added to a therapeutic regimen, careful 
attention must be paid to the incidence of systemic adverse 
reactions, in particular those affecting the cardiovascular or 
respiratory systems.
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